
The British-Swedish drug group AstraZeneca has reported disappointing results from a major study of one of its most important diabetes drugs, it reveals in a press release.
Here, AstraZeneca presents the topline data from the phase III/IV study Exscel with the company’s GLP-1 receptor agonist Bydureon (long-acting exenatide). The study compared treatment with Bydureon relative to placebo in more than 14,000 diabetes patients from 35 different countries.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app